BSX
Boston Scientific Corporation
Stock
$42.60−0.63 (−1.46%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.0B | $20.1B | $16.7B | $14.2B | $12.7B | $11.9B | $9.9B | $10.7B | $9.8B | $9.0B | $9.1B | $8.1B | $7.5B | $7.1B | $7.2B | $7.6B | $7.8B | $8.2B | $8.1B | $8.4B |
| Cost of revenue | $6.3B | $6.2B | $5.3B | $4.3B | $4.0B | $3.7B | $3.5B | $3.1B | $2.8B | $2.6B | $3.1B | $2.8B | $2.3B | $2.1B | $2.3B | $2.7B | $2.6B | $2.6B | $2.5B | $2.3B |
| Gross profit | $14.7B | $13.9B | $11.5B | $9.9B | $8.7B | $8.2B | $6.4B | $7.6B | $7.0B | $6.5B | $6.0B | $5.3B | $5.2B | $5.0B | $4.9B | $5.0B | $5.2B | $5.6B | $5.6B | $6.0B |
| R&D | $2.2B | $2.1B | $1.6B | $1.4B | $1.3B | $1.2B | $1.1B | $1.2B | $1.1B | $997M | $920M | $876M | $817M | $861M | $886M | $895M | $939M | $1.0B | $1.0B | $1.1B |
| SG&A | $7.2B | $6.9B | $6.0B | $5.2B | $4.5B | $4.4B | $3.8B | $3.9B | $3.6B | $3.3B | $3.1B | $2.9B | $2.9B | $2.7B | $2.5B | $2.5B | $2.6B | $2.6B | $2.6B | $2.9B |
| Other operating expenses | $1.2B | $1.3B | $1.3B | $949M | $1.2B | $1.4B | $1.6B | $987M | $823M | $879M | $1.5B | $1.8B | $1.8B | $1.3B | $5.3B | $677M | $2.3B | $2.8B | $3.5B | $2.0B |
| Operating income | $4.2B | $3.6B | $2.6B | $2.3B | $1.6B | $1.2B | −$80M | $1.5B | $1.5B | $1.3B | $447M | −$283M | −$301M | $120M | −$3.9B | $904M | −$656M | −$894M | −$1.5B | −$14M |
| Non-operating income | −$291M | −$228M | −$321M | −$358M | −$508M | −$123M | $1.0M | −$831M | −$84M | −$352M | −$270M | −$367M | −$208M | −$343M | −$239M | −$262M | −$407M | −$414M | −$526M | −$555M |
| Pretax income | $3.9B | $3.4B | $2.3B | $2.0B | $1.1B | $1.1B | −$79M | $687M | $1.4B | $933M | $177M | −$650M | −$509M | −$223M | −$4.1B | $642M | −$1.1B | −$1.3B | −$2.0B | −$569M |
| Taxes | $186M | $487M | $428M | $392M | $443M | $35M | $3.0M | −$4.0B | −$249M | $829M | −$170M | −$411M | −$390M | −$102M | −$39M | $201M | $2.0M | −$283M | $5.0M | −$74M |
| Net income | $3.7B | $2.9B | $1.9B | $1.6B | $698M | $1.0B | −$82M | $4.7B | $1.7B | $104M | $347M | −$239M | −$119M | −$121M | −$4.1B | $441M | −$1.1B | −$1.0B | −$2.0B | −$495M |
| Diluted EPS | $2.47 | $1.94 | $1.25 | $1.07 | $0.45 | $0.69 | −$0.08 | $3.33 | $1.19 | $0.08 | $0.25 | −$0.18 | −$0.09 | −$0.09 | −$2.89 | $0.29 | −$0.70 | −$0.68 | −$1.36 | −$0.33 |
| Diluted shares | — | 1.49B | 1.49B | 1.46B | 1.44B | 1.43B | 1.42B | 1.41B | 1.40B | 1.39B | 1.38B | 1.34B | 1.32B | 1.34B | 1.41B | 1.52B | 1.52B | 1.51B | 1.50B | 1.49B |
| Revenue growth | — | +19.9% | +17.6% | +12.3% | +6.7% | +19.9% | −7.7% | +9.3% | +8.6% | −0.3% | +12.5% | +8.1% | +5.5% | −2.4% | −4.9% | −2.4% | −4.7% | +1.7% | −3.7% | — |
| Gross margin | 69.9% | 69.0% | 68.6% | 69.5% | 68.8% | 68.8% | 65.0% | 71.0% | 71.4% | 71.3% | 65.7% | 65.7% | 69.3% | 70.3% | 67.6% | 65.1% | 66.7% | 68.5% | 69.3% | 72.0% |
| Operating margin | 19.8% | 18.0% | 15.5% | 16.5% | 13.0% | 10.1% | −0.8% | 14.1% | 15.3% | 14.2% | 4.9% | −3.5% | −4.0% | 1.7% | −53.4% | 11.9% | −8.4% | −10.9% | −18.7% | −0.2% |
| Net margin | 17.5% | 14.4% | 11.1% | 11.2% | 5.5% | 8.8% | −0.8% | 43.8% | 17.0% | 1.1% | 3.8% | −3.0% | −1.6% | −1.7% | −56.1% | 5.8% | −13.6% | −12.5% | −25.3% | −5.9% |